30 January 2015 - Biopharmaceutical company Epizyme (NasdaqGS:EPZM) reported on Thursday the appointment of Robert A. Copeland, PhD as president of its Research.

Prior to the promotion, Dr Copeland was the executive vice president of Research and chief scientific officer of the company.

The company added that Dr Copeland will continue to serve in the chief scientific officer role.

Dr Copeland recently served as vice president, Cancer Biology, of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline. Previously, he worked in scientific positions at Merck Research Laboratories and Bristol-Myers Squibb Company and in faculty position at the University of Chicago Pritzker School of Medicine.